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1. Introduction
Metallic implants are commonly used in the orthopedic field. Despite the large number of
metallic medical devices in use today, they are predominantly make up of only a few metals.
Metallic alloys such as titanium continue to be one of the most important components used in
orthopaedic implant devices due to favorable properties of high strength, rigidity, fracture
toughness and their reliable mechanical performance as replacement for hard tissues. Ortho‐
paedic implants are medical devices used for the treatment of musculoskeletal diseases and
may consist of a single type of biomaterial or comprise a number of different biomaterials
working together in modular parts. Prime examples of titanium implants used in orthopaedics
would include prosthetic hip and knee replacements for various types of arthritis affecting
these joints, spinal fusion instruments for stabilizing degenerate and unstable vertebral
segments, and fracture fixation devices of various types such as plates, screws and intrame‐
dullary rods. Although titanium based implants are typically expected to last ten years or more,
however longevity is not assured and the lack of integration into the bone for long-term
survival often occurs and leads to implant failure. Revision surgery to address such failure
involves increased risk, complications and costs. The main reason for the failure of these
implants is aseptic loosening which accounts for 60 to 70% of the cases for revision surgery.
The success of implants is dependent on firm bonding or fixation of implant biomaterial to
bone, for optimal function and lastingness. Therefore one of the key challenges in bone healing
and regeneration is the engineering of an implant that incorporates osseointegration with
enhanced bioactivity and improved implant-host interactions so as to reduce biological related
implant failure.
1.1. Development of titanium alloys for use in orthopaedics
Titanium alloys, originally used for aeronautics, garnered attention from the biomedical field,
due to their biocompatibility, low modulus of elasticity, and good corrosion resistance.
© 2013 Wang and Poh; licensee InTech. This is an open access article distributed under the terms of the
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Nonetheless, it was the osseointegration phenomenon due to the presence of a naturally
formed oxide layer on the titanium surface that sparked development of titanium for use in
orthopaedics [1]. Titanium alloys are often used in non-weight-bearing surface components
such as femoral necks and stems (Figure 1), as they have lower modulus of elasticity resulting
in less stress shielding of bone [2]. Nonetheless the osseointegrative bioactivity is still often
not sufficient to attain true adhesion between the implant and bone, which may ultimately
lead to mechanical instability and implant failure [3].
Figure 1. a) Titanium stem and (b) surface elemental analysis.
The mechanical properties of suitable titanium alloys based on Young's moduli should be
similar to that of cortical bone. Cortical bone also termed compact bone is the major and most
important constituent of the human skeleton and is crucial for bone functions including organ
protection, movement, support etc. Young's moduli of β-type titanium alloys are substantially
smaller than those of the α- and (α + β)-type alloys. This has brought on the discovery of
harmless low-rigidity Ti alloys such as Ti-13Nb-13Zr, Ti-12Mo-6Zr-2Fe, Ti-15Mo-5Zr-3Al,
Ti-15Mo, Ti-35Nb-7Zr-5Ta and Ti-29Nb-13Ta-4.6Zr. Nonetheless there are both advantages
and disadvantages of the application of these titanium alloys. These alloys have proved to be
effective in preventing bone atropy and enhancing bone remodeling, however the high amount
of spring back and low fatigue strength make them undesirable as implant material. Ti-6Al-4V
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and commercial purity Ti are currently the most popular materials for implantation purposes.
Commercial purity Ti has been tested to be inferior considering tensile strength, while Al and
V have been shown to be unsafe. Currently researchers are still trying to develop other grades
of alloys, such as Ti-6Al-7Nb and Ti–15Sn–4Nb–2Ta–0.2Pd. The most Ti alloys researched upon
are the (α + β)-type alloys for their strength and ductility.
1.2. Bioactivity of titanium alloys
Each manufacturer of titanium implants has his own differing theories on implant designs for
specific orthopaedic applications. Generally there are certain guiding principles that will affect
the ultimate viability of an implant. The design of the implant has to take into account
biomechanical and biological factors that may affect its success. Conformity to native anatomy,
material properties and mechanical strength appropriate for the targeted function and
environment are some of the considerations that come into play. Despite the benefits and
successes of these medical devices, their use is not without risk of adverse effects. Titanium
implants generally develop an oxide layer which allows it to integrate with living bone tissue.
However, the body can have adverse reactions to titanium like fibrosis and inflammation
which may affect its long term functional performance [4]. Success in the application of an
orthopaedic implant would depend on various factors and implants may fail due to physio‐
logic reasons such as aseptic loosening.
Generally there are two types of implant-tissue responses [5-7]. The first type is the response
of the hosts' tissues to the toxicity of the implanted material. Implanted material may be toxic
or release chemicals that could damage the surrounding tissues. The second response which
is also the most common is the formation of a nonadherent fibrous capsule between the implant
and the hosts' tissues termed fibrosis. This is a natural response to protect the body from a
foreign object which may eventually lead to complete fibrous encapsulation [8]. Typically
implants are intended to stay fixed in the human body for a long time and bone is expected to
grow into the surface of the implant. Unfortunately this does not always happen. Fibrosis
referred to as foreign body reaction, develops in response to almost all implanted biomaterials
and consists of overlapping phases similar to those in wound healing and tissue repair
processes [9]. Despite the biocompatibility of metallic implants used, titanium materials are
generally encapsulated by fibrous tissue after implantation into the living body [10]. Cells
trapped between the implant and the fibrous capsule also lack general housekeeping tissue
functions like removing apoptotic or necrotic cells which can also promote chronic inflamma‐
tion [11]. Not only that the ECM (extra cellular matrix) secreted by fibroblast is different from
the bone matrix formation generated by osteoblast, in the long run this ECM layer may lead
to micromotion and the generation of wear particles on the surfaces of the implant [12]. The
resulting titanium debris may play a leading role in the initiation of the inflammatory cascade
leading to osteolysis [13]. Eventually this causes aseptic loosening as the bonds of the implant
to the bone are destroyed by the body's attempts to digest the wear particles. When this occurs
the prosthesis becomes loose and the patient may experience instability and pain. Revision
surgery to resolve this would entail further costs and morbidities to the patients. For bone
tissue, direct osteoblast attachment on metal is important to prevent aseptic loosening of the
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metal implant caused by fibroblast layer attachment. Fibrosis can also cause osteoclast-
independent bone resorption by fibroblast-like cells. It has been shown that fibroblast-like cells,
under pathological conditions, not only enhance but also actively contribute to bone resorption
[14]. Successful implant integration into the surrounding tissue is highly dependent on the
crucial role of native cells, chiefly osteoblast attaching to the implant surface. Therefore one of
the key challenges in orthopaedics is the engineering of an implant with enhanced osseointe‐
gration properties to reduce implant failure rates.
Figure 2. Schematic figure of a hip implant. The femoral neck is the region at risk of compromised vascularity. Arrows
indicate area of compromised vascularity where osseiointegration fails to take place.
2. Strategies for conferring enhanced bioactivity to titanium alloys
So far most research efforts have been concentrated on improving the bone-implant interface,
with the aim of enhancing bone healing and implant integration via either physical or chemical
approaches [15]. The physical approach is focused on the modification of the implant surface
morphology and topography using mechanical methods such as machining, acid-etching,
plasma spraying, grit-blasting and anodization to improve the microtopography of the surface.
The rationale behind this is that an increase in surface roughness of the implant material would
provide a higher level of surface energy which would improve bone anchorage, matrix protein
adsorption, osteoblasts functions and ultimately osseointegration [16].
The chemical approach is towards the creation of a bioactive implant surface via application
of coatings onto the implant layer by biochemical and physicochemical techniques. In bio‐
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chemical techniques, organic molecules such as growth factors, peptides or enzymes are
incorporated to the implant layer to affect specific cellular responses [17]. While in physico‐
chemical techniques, the incorporation is achieved with inorganic phases such as calcium
phosphate which may increase the biochemical interlocking between bone matrix proteins and
surface materials thereby enhancing bone-bonding [16]. Many implant modifications may
combine both physical and chemical engineering methods. In the following sections we will
discuss some of the more popular strategies used to enhance implant integration and bone-
bonding.
2.1. Inorganic coatings
Calcium phosphate coating has been widely used in the orthopaedic field due to their
similarity with the mineral phase of bone [18] and are known for their bioactive properties
which are beneficial in bone-bonding [19]. As calcium phosphate generally lacks the mechan‐
ical strength for use as bulk materials under loading conditions, they are often coated onto the
surface of metallic implants. There are several studies published which have shown the
favorable use of calcium phosphate coatings in increasing the biocompatibility of bone-implant
interface, implant anchorage and integration [20]. The calcium phosphate layer functions as a
physiological transition between the implant surface and the hosts' tissues which guides bone
formation along the implant surface and the surrounding tissues. One of the most successful
method for the application of calcium phosphate coatings is via the plasma-spraying method
due to its advantage of extensive coating capability and high deposition rate. However despite
numerous findings [21] that report the beneficial osteoinductive properties of plasma-sprayed
calcium phosphate coatings, there are still some concerns regarding its use. Plasma-sprayed
coatings are not uniform and there is poor control over thickness and surface topography,
which may result in implant inflammation when particles are released from these heteroge‐
neous coatings. To overcome these drawbacks, various other deposition strategies have been
developed and employed such as biomimetic, electrophoretic and electrospray deposition etc.
However care should be taken when comparing the efficacy of each of these methods which
would require a comprehensive evaluation of both biological response and clinical perform‐
ance. Although calcium phosphate coatings have been shown to be beneficial in enhancing
bone-bonding, there is still no general consensus on the use of calcium phosphate coating
systems. The main problems include large variation in the quality of calcium phosphate
coatings, even between different batches and market forces which offer other cheaper alter‐
natives [22].
2.2. Organic coatings
Surface  modification  of  implant  materials  with  growth  factors  and  peptides  is  gaining
popularity in the recent years [23, 24]. Various therapeutic biomolecules of interest can be
immobilized  onto  implant  surfaces  to  enhance  the  bone-implant  interface  interactions.
Currently  more  popular  approaches  would  include  the  immobilization  of  bone  growth
factors  such  as  bone  morphogenetic  proteins  (BMPs)  to  enhance  osteogenesis  and  the
deposition  of  peptide  sequences  to  induce  specific  cellular  functions.  Growth  factors
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immobilized on orthopaedic  devices have been reported to enhance osteoblastic  activity
and favor implant integration [25]. The most commonly used growth factors in orthopae‐
dics are members of the transforming growth factor beta (TGF-β) superfamily including
the BMP family, especially BMP2 and BMP7. Growth factors may be physically adsorbed
or covalently grafted onto the implant surface and various studies have shown that  the
loading of implant with these factors can enhance interactions at the bone-implant interface
and aid the remodeling process ultimately improving implant integration [26-28]. Howev‐
er  critical  factors  in  the  successful  use  of  growth factors  in  orthopaedic  devices  are  the
optimum dosage, exposure period and release kinetics, all have to be considered careful‐
ly to avoid the detrimental effects associated with growth factor use such as high initial
burst rate, ectopic bone formation and short half-life. More recently, peptide sequences with
the ability to target specific osteogenic cellular functions of differentiation and mineraliza‐
tion  have  been  developed  [29,  30].  These  short  functional  fragments  derived  from  the
original  protein  have  increased  shelf  life,  can  be  synthetically  produced  and  are  more
resistant to denaturizing effects. Their usage would provide significant clinical benefits over
the  use  of  conventional  proteins.  They can be  linked to  the  implant  surface  to  provide
biological cues for bone formation. Additionally other peptide sequences in use include the
RGD, YIGSR, IKVAV and KRSR which have been used to improve cellular adhesion and
bone matrix formation [31-33].
2.3. Organic–inorganic composite coatings
Research in the recent years have concentrated on the development of bioactive compo‐
site coatings which mimics the structure of the bone tissue. These composite coatings would
combine  calcium  phosphate  with  growth  factors,  peptides,  antibodies  etc.  to  enhance
interactions  at  the  bone-implant  interface.  However  due  to  the  fact  that  often  high
temperature  or  non-physiological  conditions  are  needed  in  the  preparation  of  calcium
phosphate coatings,  only physical  adsorption is  employed in deposition of  the biomole‐
cules on the implant surface [34, 35]. However with physical adsorption techniques, initial
high burst rate is often observed, which is not desired [36]. Therefore coating techniques
that  create  a  gentle  sustained release  kinetics  are  preferred.  A recently  published paper
have shown that calcium phosphate coating combining slow release of antibiotics, aids in
early  success  at  recruitment  of  bone  cells  [37].  Many  other  studies  have  shown  that
depositing  BMP2  and  TGF-β  onto  the  implant  surface  would  greatly  enhance  bone-
bonding  at  the  bone-implant  interface  [25,  34].  The  biological  efficacy  of  orthopaedic
implants can be improved greatly by both physical and chemical modifications. The use of
a  wide multitude of  engineering techniques  in  the  manipulation of  surface  topography,
morphology and incorporating the use of various inorganic and organic components would
directly influence the response in the local  bone-implant interface and the apposition of
new bone. With the development of new techniques and strategies on composite coatings
to  better  mimic  the  human  bone  structure  this  would  result  in  a  new  generation  of
orthopaedic implants with improved implant integration and bone healing.
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3. Osseointegration of the implants
The clinical strategies to manage musculoskeletal defects would center around three compo‐
nents: cells, structure and growth factors. For the design of implant materials, cells and proteins
at the implant interface plays a critical role [38]. The utilization of biosignal proteins such as
growth factors for development of bioactive implant materials holds great potential. Especially
due to the scarcity of stem cells in the body, materials which regulates cellular functions such
as adhesion, growth and differentiation are desired.
One of the most important process in determining the success of an orthopaedic implant is
osseointegration. Osseointegration is defined as the formation of a direct structural and
functional connection between the living bone and the surface of a implant [39, 40]. An implant
is considered osseointegrated if there is no progressive relative movement between the implant
and the bone it has direct contact with [40]. Under ideal conditions, implants could perma‐
nently become incorporated within the bone and persist under all normal conditions of
loading, that is the two could not be separated without fracture. Vascularization which is the
provision of blood supply is a critical component for the process of osseointegration. The
differentiation of osteogenic cells is highly dependent on tissue vascularity and ossification is
closely linked to the vascularization of differentiating tissue [40]. Therefore the success of tissue
healing, regeneration and integration lies in the key process of revascularization which is
crucial in improving the successful integration of implants [41, 42].
Bone healing around implants involves a cascade of cellular and biological events that take
place at the bone-implant interface until finally the entire surface of the implant is covered by
newly formed bone. This cascade of biological events is regulated by differentiation of cells
stimulated by growth factors secreted at the bone-implant interface [40]. There has been
considerable interest in modifying implant surfaces with growth factors to improve their cell
functions and tissue integration capacity at the bone-implant interface. Enhanced cell functions
and cell substrate interactions have been demonstrated with growth factors immobilized onto
implant materials [26-28]. One of the more important growth factors for stimulating neovas‐
cularization (i.e. formation of new blood vessels) in target areas [43] would be angiogenic
growth factors, crucial in improving the successful integration of implants both in vitro and in
vivo [41, 42]. Of these angiogenic factors, vascular endothelial growth factor (VEGF) is the most
potent and widely used key regulator of neovascularization [43, 44]. VEGF is a crucial factor
in not only angiogenesis regulation but also in osteoblast [45] and osteoclast function [46-48]
during bone repair. VEGF acts directly on osteoblasts, promoting cell functions such as
proliferation, migration and differentiation [49, 50]. In addition, VEGF also indirectly affect
osteoblasts via its influences on endothelial cells [51, 52]. VEGF is known to induce endothelial
cells in surrounding tissues to migrate, proliferate and form tubular structures [53] and is an
essential survival factor for endothelial cells [51] and new vessel formation [54]. Endothelial
cells are needed to provide complex interactive communication networks in bone for gap
junction communication with osteoblasts crucial to their formation from osteoprogenitors [55].
Furthermore VEGF stimulates endothelial cells in the production of beneficial bone forming
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factors acting on osteoblasts [50]. In all, the effects of VEGF on osteoblasts, osteoclasts and
endothelial cells may synergistically act to enhance bone formation.
3.1. Fixation of titanium implants
The fixation of prosthetic components to the bone can be done with or without bone cement.
In the cemented technique polymethylmethacrylate (PMMA) is used to "glue" the metal to
the bone. In direct biological fixation, precise bone cuts are required to achieve maximum
contact between metal and bone. The advantage of cement fixation is that the prosthetic
components are instantly fixed, allowing movement immediately after surgery. However
in the instances where revision surgery is required, it is extremely difficult to chip out all
the cement during implant replacement. Cement fixation is usually employed on elderly
patients over sixty-five where their bone stock is more osteoporotic with less likelihood of
growing into the prosthesis and chances of revision is lower due to less demands on the
implant  and  shorter  remaining  life  expectancy  compared  to  younger  patients.  Direct
biological  fixation  is  generally  used  for  young  patients  due  to  better  bone  stock  and
ingrowth potential.  The  disadvantage  of  biological  fixation  is  that  it  can  take  weeks  or
months to be fully complete during which weight bearing activity is restricted. However
the final fixation achieved is more natural with complete incorporation of implant within
the bone in ideal situations. Furthermore in case of young patients the chances for future
revision surgery is higher and it would be easier to revise a cementless prosthesis with‐
out the need for cement removal. Another problem perceived was that cementless titani‐
um stems have been reported to  be  more  resistant  to  osteolysis  and mechanical  failure
compared  to  similar  cemented  titanium  stems  [56].  The  features  of  titanium  that  are
detrimental to the cement environment seems to have no effects in the cementless environ‐
ment  and  may  in  fact  be  beneficial  leading  to  differences  in  performance  of  the  two
techniques.  Therefore the enhancement of the bone implant interface especially in direct
biological fixation with titanium implants would be extremely useful. This would greatly
reduce  the  lag  period  in  which  osseointegration  occurs  between the  prosthesis  and the
patient's bone.
3.2. Surface functionalization by growth factors immobilization
One promising way to incorporate growth factors usage with implant materials would be by
surface functionalization of growth factors. Soluble growth factors work by binding with
cognate receptors on cells to form complexes which would result in autophosphorylation of
the cytoplasmic domains of the receptors and this phosphorylation activates intracellular
signal transduction. The formed complexes are then aggregated and internalized into the cells
by both clathrin-dependent and clathrin-independent mechanisms which leads to the recy‐
cling of the receptors for degradatory down-regulation [57]. Similarly immobilized growth
factors work by forming complexes with the cell surface receptors, however the signal
transduction is expected to last longer than soluble growth factors due to the inhibition of the
internalization process. Multivalency is another important phenomenon responsible for this
prolonged enhanced mitogenic effect. Multivalent ligands interact and bind avidly to multiple
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surface cell receptors through several binding modes. This enhances the formation of ligand-
receptor complexes which are critical for signal transduction and the multivalent ligands are
able to stabilize and prevent lateral diffusion of the formed complexes leading to the prolonged
effect. Figure 3 shows the interactions of cells with the different forms of growth factor and
the enhanced mitogenic effects.
Figure 3. Effects of soluble growth factors compared to immobilized growth factors.
In order to effectively derive the effect from immobilized growth factors, strategies have to be
developed that can optimize the structure to elicit the desired biological response. One of the
problems encountered with implant materials for surface functionalizaton is the lack of
suitable chemical groups on the surface. For more versatility and applicability, the concentra‐
tions of the OH group and other reactive groups such as amino or carboxyl groups have to be
increased. The initial organic layer immobilized on the implant materials can then be used as
a tether for biomolecular components used to mediate cell attachment. Another issue which
merits investigation is the control of the retention and/or release of the biomolecules from the
implant surface. The easiest and most common method employed for delivery of biomolecules
is physical adsorption, which unfortunately provides little control over the delivery and
orientation of the biomolecules. Bonding of the biomolecules and use of coatings incorporating
them would be alternative methods of delivery to the bone-implant interface. Regardless, the
preferred and chosen immobilization technique would depend on the specific working
mechanism of the biomolecules. Given the above scenario, surface functionalization of
biomaterials in order to enhance biocompatibility and promote osseointegration has great
potential in addressing the problems of prosthetic joint implant longevity and survival.
Immobilization techniques are broadly classified into four categories, namely a) physical
adsorption (via van der Waals or electrostatic interactions), b) physical entrapment (use of
barrier systems), c) cross-linking and d) covalent binding. The choice of the technique would
depend on the nature of the bioactive factors, substrates and its application. It will not be
possible to have a universal means of immobilization, however developing a viable method‐
Titanium Alloys in Orthopaedics
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ology which can provide for a facile, secure immobilization with good interactions for
orthopaedic implants is vital.
3.2.1. Physical adsorption
This is the simplest of all the techniques available and does not alter the activity of the bioactive
factors. Physical adsorption techniques are mainly based on ionic and hydrophobic interac‐
tions. If the bioactive factors are immobilized via ionic interactions, adsorption and desorption
of the factors will depend on the basicity of the ion exchanger. A reversible dynamic equili‐
brium is achieved between the adsorbed factors and substrates which is affected by the pH as
well as ionic strength of the surrounding medium. Hydrophobic interactions offer slightly
higher stability with less loss of the factors from the surface of the substrates. Although physical
adsorption systems are simple to perform and do not require extensive treatment to the
bioactive factors and substrates used however there are certain drawbacks. These systems
suffer from low surface loading and biomolecules may desorbed from the surface in an
uncontrolled manner.
Figure 4. Schematic diagram showing physical adsorption system with proteins.
3.2.2. Physical entrapment
This method is employed with barriers including natural polymers like gelatin, agar and
alginate entrapment systems. Other synthetic polymers employed include resins, polyur‐
ethane prepolymers etc. Some of the major limitations of the entrapment system is the
diffusional problem where there is possible slow leakage during continuous use due to the
small molecular size of bioactive factors, and steric hindrance which may affect the reactivity
of the factors. Recent development of hydrogels and water soluble polymers attempt to
overcome these drawbacks and have attracted much attention from the biomedical field.
Figure 5. Schematic diagram showing barrier system with proteins.
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3.2.3. Cross-linking
Bioactive factors can also be immobilized through chemical cross-linking via homo- as well as
heterobifunctional cross-linking agents. Among these glutaraldehyde cross-linking are the
most popular due to its low cost, high efficiency and stability [58-60]. Glutaraldehyde is often
used as an amine reactive homobifunctional crosslinker for biochemistry applications.
Figure 6. Schematic diagram showing glutaraldehyde cross-linking with proteins.
3.2.4. Covalent binding
Covalent binding is another technique used for the immobilization of bioactive molecules. The
functional groups investigated are usually the carboxyl, amino and phenolic group of tyrosine.
Bioactive factors are covalently linked through functional groups in the factors not essential
for the bioactivity. The covalent binding should be optimized so as to protect the active site
and not alter its conformational flexibility.
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Figure 7. Schematic diagram showing polymerization of dopamine under alkaline pH and the equilibrium shift to‐
wards the quinone functional groups for reactivity with proteins.
3.2.5. Comparison of the various immobilization techniques
Several methods of immobilizing angiogenic growth factors onto substrates have been studied
and reported [61-66]. A summary of a short study investigating the efficacy of immobilization
of VEGF via various modes of functionalization on Ti-6Al-4V including physical adsorption,
cross-linking and covalent binding (adapted for orthopaedic applications) is presented here
to evaluate the effectiveness of each technique. As physical entrapment is not suitable in this
case of improving the bone-implant interface via the surface of the implant material, therefore
this system is not investigated. Table 1 summarizes the parameters of the binding efficiency,
cytotoxicity, release profile and number of steps required for the fabrication of the substrates.
Although physical adsorption had the highest rate of binding however there was also
uncontrolled release of the factors from the substrate which may be undesirable [67-69]. A
measurement of the percentage of factors released into the solution over a 30 day period
showed that more than 30% of the factors were released. A number of studies have examined
simple coating or loading of factors onto implants [67-73] in order to provide local and
sustained delivery after implantation. However with this strategy some studies showed an
uncontrolled initial burst in the release kinetics of factors from such implants [67-69]. High
levels of factors in the local microenvironments of these implants may be detrimental to healing
and may promote tumorogenesis [74]. To avoid the deleterious effects, secure immobilization
strategy would be preferred [61, 64-66]. Immobilization of growth factors on implants have
been shown to promote desirable cell substrate interactions and enhance cell functions [62,
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63]. Furthermore it has been demonstrated that immobilized factors is more effective in
promoting proliferation of cells compared to soluble factors [65]. Both immobilized and soluble
factors bind to receptors on cells, however they have differing effects due to the fact that soluble
factors are internalized and subsequently degraded, while immobilization inhibits internali‐
zation and prevents down regulation [64, 75], thereby enabling the factors to stimulate
proliferation for an extended period of time. A comparison of cross-linking and covalent
binding shows that they come quite close in terms of binding efficiency and there is no release
of growth factors into the solution which is the preferred methodology.
From the cytotoxicity indications (Table 1) follows that there is a lower cell viability with
glutaraldehyde cross-linking compared to the other groups. This may be due to the fact that
glutaraldehyde is known to be toxic and is able to kill cells quickly by cross-linking with their
proteins. There have also been reports of its toxicity implicated in poor cell growth, attachment
and apoptosis [58-60] by other groups. Although glutaraldehyde cross-linking effectively
anchors a high density of factors onto the titanium substrate surface and the molecules are also
more firmly attached than those which are physically adsorbed however the associated toxicity
has made it unsuitable for clinical applications. The use of covalent immobilization with
polydopamine looks promising. Polydopamine has been found to be able to form thin adherent
films onto a wide variety of metallic substrates via covalent bonds and various strong inter‐
molecular interactions including metal chelation, hydrogen bonding and π-π interactions [76]
which cannot be disrupted by normal mechanical forces. The use of this bioreactive layer for
covalent bioconjugation with bioactive factors for orthopaedic applications holds great
potential. Although it will not be possible to have a universal means of immobilization,
however it is vital to develop a viable methodology which can provide for secure immobili‐
zation with good interactions for orthopaedic implants. The choice of the technique would
depend on the nature of the bioactive factors, substrates and their application. The develop‐
ment of surface modification procedures that do not affect the integrity of the substrate and
bioactivity of the growth factors are crucial in producing the desired surface functionalization
effect. This would provide us with a secure and efficient method of attaching bioactive
Binding
Efficiency
(50ng loading)
Cytotoxicity Factor releaseovertime Active form
Number of steps
required for
fabrication
Physical adsorption
(via simple coating) 86% 0.677
"/> 30% after 1
month Soluble Single step
Cross-linking
(via glutaraldehyde
cross-linking)
56% 0.449 Nil Immobilized Three steps
Covalent Binding
(via polydopamine
conjugation)
52% 0.841 Nil Immobilized Two steps
Table 1. please add caption
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molecules to titanium implant material surface conferring enhancement of cell-implant
interactions beneficial for orthopaedic applications.
4. Conclusions
There is an ever growing need for orthopaedic advancement with the high prevalence and
impact of musculoskeletal diseases. 50% of the world's population over 65 suffer from joint
diseases and more than 25% of population over 65 require health care for joint related diseases.
The instances for failed joint replacements associated with osteolysis and bone defects is
increasing. There is an urgency to increase the success of bone implant fixation and the
longevity of implant. Fixation of orthopaedic implants has been one of the most challenging
and difficult problem faced by orthopaedic surgeons and patients. Fixation can often be
achieved via direct biological fixation by allowing tissues to grow into the surfaces of the
implants or with the use of bone cement acting as a grouting material. Whether cemented or
cementless fixation are employed, the problems of micromotion and the generation of wear
particles may eventually necessitate further surgery. Revision surgery poses increased risks
like deep venous thrombosis, infection and dislocation, in addition to being an economic
burden to the patient. Therefore the enhancement of implant integration would bring enor‐
mous benefits. Titanium alloy is one of the most frequently used material in orthopaedic
implants. However despite the good inherent bioactivity and biocompatibility exhibited by
titanium alloys, osseointegration with host tissue is still not definite, the lack of bioactivity may
cause implant failure at times. Fixation of orthopaedic implants has been one of the most
challenging and difficult problem faced by orthopaedic surgeons and patients. With the ever
growing number of patients requiring orthopaedic reconstructions the development and
evolvement of titanium alloys with structural and biological potential to manage bone healing
impairment and defects would be desirable.
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